Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-222 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 12 week treatment | EXPERIMENTAL | - |
| 16 week treatment | EXPERIMENTAL | - |
| Quadruple Regimen | EXPERIMENTAL | All subjects will receive active study drugs (quadruple regimen: VX-222, telaprevir,Peg-IFN, and RBV) for a fixed treatment duration of 24 weeks. |
| Name | Type | Description |
|---|---|---|
| VX-222 | DRUG | 400 mg tablets twice daily for oral administration |
| telaprevir | DRUG | 1125 mg tablets twice daily for oral administration |
| ribavirin | DRUG | 1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily |
| peginterferon-alfa-2a | BIOLOGICAL | subcutaneous injection, 180-mcg, once weekly |
Inclusion Criteria: * Subjects must have genotype 1 chronic hepatitis C (CHC) and laboratory evidence of HCV infection for at least 6 months before the Screening Visit * Subjects will be treatment naïve * Subjects must have documentation of the presence or absence of cirrhosis Exclusion Criteria: ...
VX-222 is an investigational small molecule being studied for the treatment of chronic hepatitis C virus infection. It was evaluated in Phase 2 clinical trials in combination with other antiviral agents, including telaprevir, peginterferon-alfa-2a, and ribavirin, in patients with chronic hepatitis C, including those with compensated cirrhosis.
VX-222 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company conducted Phase 2 clinical trials of VX-222 in patients with chronic hepatitis C virus infection.
VX-222 is in Phase 2 clinical development. It has completed two Phase 2 trials, both of which are finished, and no active trials are currently listed. The drug remains investigational and has not been approved by regulatory authorities.
VX-222 has been studied in two completed Phase 2 clinical trials. The first, NCT01516918, evaluated quadruple therapy with VX-222, telaprevir, peginterferon-alfa-2a, and ribavirin in 103 patients with chronic hepatitis C and compensated cirrhosis. The second, NCT01581138, studied VX-222 plus telaprevir and ribavirin for 12 or 16 weeks in 64 treatment-naive patients with genotype 1a hepatitis C.
No, VX-222 is not the same as telaprevir. VX-222 is a separate investigational drug developed by Vertex Pharmaceuticals. In clinical trials, VX-222 was studied in combination with telaprevir, which is a different antiviral agent, along with peginterferon-alfa-2a and ribavirin, for the treatment of chronic hepatitis C virus infection.